Drug main Cipla on Thursday introduced the commercialisation of its RT-PCR take a look at equipment ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems.
“This launch will help address the current testing services and capacity issues while reaffirming the company’s ongoing expansion in the diagnostic space,” Cipla stated in a regulatory submitting.
Cipla will launch ViraGen take a look at equipment within the nation in partnership with Ubio Biotechnology Systems, the corporate said.
The firm will begin provide of the COVID-19 virus detection equipment from May 25, 2021.
Umang Vohra, MD and Global CEO, Cipla, stated, “Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19. Guided by our core purpose of ‘Caring for Life’, this partnership will enable us to reach out to more people across the country at a crucial time like now”.
ViraGen is Cipla’s third providing within the COVID-19 testing section.
